Skin Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Skin Cancer, including details on identification, causes, prevention, treatment.

Volume 2 (2005), Issue 10 (October)

1. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
   Lancet, 366(9492): 1189-96. [Abstract] [Full-text]
2. Interstitial brachytherapy of periorificial skin carcinomas of the face: a retrospective study of 97 cases.
   Int J Radiat Oncol Biol Phys, 63(3): 753-7. [Abstract] [Full-text]
3. Clinicopathological features of and risk factors for multiple primary melanomas.
   JAMA, 294(13): 1647-54. [Abstract] [Full-text]
4. Attenuated familial adenomatous polyposis and Muir-Torre syndrome linked to compound biallelic constitutional MYH gene mutations.
   Clin Genet, 68(5): 442-7. [Abstract] [Full-text]
5. CD8 T cells expressing NK associated receptors are increased in melanoma patients and display an effector phenotype.
   Cancer Immunol Immunother, 54(12): 1162-71. [Abstract] [Full-text]
6. Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers.
   Cancer Gene Ther, 12(11): 864-72. [Abstract] [Full-text]
7. Identification of an X-linked locus modifying mouse skin tumor susceptibility.
   Mol Carcinog, 44(3): 212-8. [Abstract] [Full-text]
8. Deep intracranial extension of squamous cell carcinoma of the scalp.
   Pediatr Blood Cancer, 45(7): 994-6. [Abstract] [Full-text]
9. Clinical significance of CXCR3 and CXCR4 expression in primary melanoma.
   Int J Cancer, 117(5): 861-5. [Abstract] [Full-text]
10. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma.
    Int J Cancer, 117(5): 825-30. [Abstract] [Full-text]
11. High constant incidence rates of second cutaneous melanomas.
    Int J Cancer, 117(5): 877-9. [Abstract] [Full-text]
12. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
    J Natl Cancer Inst, 97(20): 1507-15. [Abstract] [Full-text]
13. Vesicular mycosis fungoides.
    J Dtsch Dermatol Ges, 3(11): 898-900. [Abstract] [Full-text]
14. Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies.
    Carcinogenesis, 26(11): 1856-67. [Abstract] [Full-text]
15. Cutaneous cysts of the head and neck.
    J Oral Maxillofac Surg, 63(11): 1613-9. [Abstract] [Full-text]
16. Increased incidence of melanoma in renal transplantation recipients.
    Cancer, 104(9): 1962-7. [Abstract] [Full-text]
17. Raised expression of the antiapoptotic protein ped/pea-15 increases susceptibility to chemically induced skin tumor development.
    Oncogene, 24(47): 7012-21. [Abstract] [Full-text]
18. Fate of UVB-induced p53 mutations in SKH-hr1 mouse skin after discontinuation of irradiation: relationship to skin cancer development.
    Oncogene, 24(47): 7055-63. [Abstract] [Full-text]
19. Diphenylmethyl selenocyanate inhibits DMBA-croton oil induced two-stage mouse skin carcinogenesis by inducing apoptosis and inhibiting cutaneous cell proliferation.
    Cancer Lett, 230(1): 90-101. [Abstract] [Full-text]
20. A population-based validation of the American Joint Committee on Cancer melanoma staging system.
    J Clin Oncol, 23(31): 8065-75. [Abstract] [Full-text]
21. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
    J Clin Oncol, 23(31): 8057-64. [Abstract] [Full-text]
22. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma.
    J Clin Oncol, 23(31): 8048-56. [Abstract] [Full-text]
23. Lymphatic mapping in management of patients with primary cutaneous melanoma.
    Lancet Oncol, 6(11): 877-85. [Abstract] [Full-text]

© 2004-2008 Skin Cancer Research Today. All Rights Reserved.